Logo of amjphAmerican Journal of Public Health Web SiteAmerican Public Health Association Web SiteSubmissionsSubscriptionsAbout Us
Am J Public Health. 2004 May; 94(5): 741–744.
PMCID: PMC1448329

Cancer Burden From Arsenic in Drinking Water in Bangladesh

Yu Chen, MPH and Habibul Ahsan, MD, MMedSc


We assessed the potential burden of internal cancers due to arsenic exposure in Bangladesh. We estimated excess lifetime risks of death from liver, bladder, and lung cancers using an exposure distribution, death probabilities, and cancer mortality rates from Bangladesh and dose-specific relative risk estimates from Taiwan. Results indicated at least a doubling of lifetime mortality risk from liver, bladder, and lung cancers (229.6 vs 103.5 per 100 000 population) in Bangladesh owing to arsenic in drinking water.

Groundwater contamination caused by inorganic arsenic is a massive public health hazard in Bangladesh.1–4 The millions of hand-pumped tube wells installed since the 1970s have led to 95% of the country’s 130 million residents becoming dependent on supposedly pathogen-free underground water.5 It is estimated that 25 to 57 million people in Bangladesh have suffered chronic exposure to arsenic,1,5 and because decades of exposure have already accrued, the exposed population is at an elevated risk of arsenic-induced health problems.

The principal cause of arsenic-induced mortality is cancer,6–10 but little is known regarding future cancer mortality risks attributable to arsenic exposure among the population of Bangladesh.1 The goal of the present study was to estimate excess lifetime mortality rates for the most-established arsenic-related internal cancers (i.e., lung, liver, and bladder cancers)7–10 in Bangladesh.


Calculation of lifetime excess risks due to a particular exposure requires measures of distribution of the exposure, “background” lifetime risks, and dose-specific relative risk estimates. In the present study, these measures were estimated as follows.

The arsenic exposure distribution in Bangladesh was ascertained from a sample of 65 876 people who represented the source population of an ongoing prospective cohort study focusing on the health effects of exposure to arsenic in drinking water. Water samples from 5966 contiguous hand-pumped tube wells in a well-defined geographic area of Araihazar, Bangladesh, were collected and tested for arsenic in 2000. Well owners were interviewed to collect data on the numbers and characteristics of the 65 876 regular users.11

Gender-specific lifetime mortality risks from liver, bladder, and lung cancers among the population of Bangladesh were derived, via life table methods, from the formula ΣS(tk)Pk. Values of S(tk) indicate the probability of surviving to the beginning of each of the 5 (i.e., k = 1–5) age groups assessed (0–14, 15–44, 45–54, 55–64, ≥65 years). Survival estimates were based on gender- and age-specific death probabilities among the overall population of Bangladesh.12 Values of Pk indicate gender-, age-, and cancer-specific mortality rates in Bangladesh; these rates were computed by the International Agency for Research on Cancer (IARC).13–16

Gender-specific, age-adjusted relative risks of liver, bladder, and lung cancer mortality due to arsenic exposure were computed on the basis of gender- and age-specific data on arsenic exposure, cancer mortality, and at-risk population obtained from studies conducted in Taiwan (detailed data regarding a published study17 were obtained from C. J. Chen and L. Ryan, January 2002). We used Poisson regression models in calculating these risk estimates, allowing us to compare rates for different levels of arsenic exposure in an endemic area with those in the general population of Taiwan.

Finally, we estimated lifetime excess mortality risks attributable to different levels of arsenic exposure by multiplying gender-specific, age-adjusted excess relative risks from Taiwan by the corresponding category-specific lifetime risks for each cancer in Bangladesh. We weighted these estimates by the arsenic exposure distribution ascertained from our study population in Bangladesh to derive overall lifetime excess risk estimates.


Results showed that, among the overall population of Bangladesh, lifetime mortality risks (per 100 000 population) of cancer of the bladder, lung, and liver were 5.4, 159.1, and 9.2 for males and 0.3, 23.1, and 9.5 for females, respectively. The overall mortality risk for the 3 cancers in combination was 103.5 per 100 000 (Table 1).

Cumulative Lifetime (Background) Mortality Risks (per 100 000 Population) From Bladder, Liver, and Lung Cancers: Bangladesh, 2000

Lifetime excess risks (per 100 000 population) of mortality from liver, bladder, and lung cancers attributable to arsenic in drinking water were 0.9, 21.5, and 175.9 for males and 3.4, 2.1, and 48.3 for females, respectively (Table 2). Overall lifetime excess mortality risks (per 100 000) from the 3 cancers in combination were 198.3 for males and 53.8 for females, with an average across-gender lifetime risk of 126.1.

Lifetime Excess Mortality Risks (per 100 000 Population) From Bladder, Liver, and Lung Cancers: Bangladesh


Our study indicates a more than doubling of future excess mortality in Bangladesh owing to cancer of the lung, liver, and bladder resulting from exposure to arsenic in drinking water (i.e., a rate of 229.6 per 100 000 population vs the background overall risk of 103.5 per 100 000 population). Our analyses employed a straightforward method measuring excess lifetime risks on an additive scale. A similar approach has been applied to predict the cancer burden due to arsenic exposure in the United States.18

Several uncertainties involved with our estimations warrant caution in interpreting our findings. First, in generating our exposure distribution, we were unable to pool data from other large-scale surveys conducted in Bangladesh since water samples in those surveys were not collected in a systematic manner and the population distributions of the individual exposure categories were unknown. However, the extent of arsenic contamination in our study area was comparable to estimates reported in those large-scale surveys.2,5,19

Second, the dose-specific relative risk estimates we used in predicting risks were derived from Taiwan data, since no such estimates are currently available in Bangladesh. Data from Taiwan have also been used in most arsenic risk assessments for the US population.18,20–22 Given the long latency of arsenic-induced cancer and the similarity in durations of well water use between the exposed populations of Taiwan (1910s–1970s)7 and Bangladesh (since the 1940s),19 the effects of arsenic are assumed to be similar in the 2 populations.

Although our relative risk estimates did not demonstrate a strict dose–response pattern, lifetime excess risk estimates did not change appreciably when the exposure categories were grouped differently (data not shown). However, the impact of potential differences in the distributions of other risk factors related to the studied cancers between the populations of Bangladesh and Taiwan is unknown. The prevalence of cigarette smoking among Bangladeshi men (56–72%) is higher than the prevalence reported in the Taiwan study from which we generated the present relative risk estimates (32%), and nutritional deficiency is more prevalent in Bangladesh.23–25 Hepatitis B virus infection was probably more prevalent in Taiwan in the 1980s, the period during which the relative risk estimates used in the present study were derived.26,27 Whether the 2 populations are comparable in terms of arsenicrelated genetic factors is unknown.

Finally, the IARC estimated cancer mortality rates for Bangladesh on the basis of cancer incidence rates in India, age-specific cancer ratios in Bangladesh, and cancer survival rates in developing countries.13–16 Because cancer mortality data are scant in Bangladesh, it is difficult to evaluate the validity of the IARC estimates. However, given the geographic and sociocultural similarities of India and Bangladesh, and the dissimilarity of the 2 countries in regard to arsenic exposure, the IARC estimates are probably the best data available for estimating “background” lifetime risks.

In conclusion, our results suggest at least a doubling of the potential cancer burden in Bangladesh due to arsenic exposure. Measures focusing on reductions in arsenic exposure, early diagnosis, and treatment of arsenic-induced cancers are thus urgently warranted. In addition, risk estimates derived directly from individual-level data are needed for more precise risk assessments tailored to the population of Bangladesh. Prospective analyses based on our ongoing epidemiological cohort study will address this issue in the near future.


This work was supported in part by US National Institute of Environmental Health Sciences grants P30 ES09089 and P42 ES10349.

We acknowledge Faruque Parvez, Joseph Graziano, Alexander van Geen, and Iftikhar Hussain for their contribution in generating the data that provided the basis for our estimation of the arsenic exposure distribution in Bangladesh. We also acknowledge the generosity of Chien-Jen Chen of the National Taiwan University, who provided us with the original data on cancer mortality rates and arsenic exposures in Taiwan, and Jacques Ferlay of IARC, who provided detailed insights regarding IARC data.

Human Participant Protection…No protocol approval was needed for this study.


Contributors…H. Ahsan conceptualized and designed the study. Y. Chen conducted data analyses and led the writing of the article.

Peer Reviewed


1. MacDonald R. Providing clean water: lessons from Bangladesh. BMJ. 2001;322:626–627. [PMC free article] [PubMed]
2. Chowdhury UK, Biswas BK, Chowdhury TR, et al. Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ Health Perspect. 2000;108:393–397. [PMC free article] [PubMed]
3. Mudur G. Half of Bangladesh population at risk of arsenic poisoning. BMJ. 2000;320:822. [PMC free article] [PubMed]
4. Smith AH, Lingas EO, Rahman M. Contamination of drinking water by arsenic in Bangladesh: a public health emergency. Bull World Health Organ. 2000;78:1093–1103. [PMC free article] [PubMed]
5. British Geological Survey. The groundwater arsenic problem in Bangladesh (phase 2). Available at: http://www.bgs.ac.uk/arsenic. Accessed January 10, 2003.
6. Chen CJ, Kuo TL, Wu MM. Arsenic and cancers. Lancet. 1988;1:414–415. [PubMed]
7. Chen CJ, Chen CW, Wu MM, Kuo TL. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer. 1992;66:888–892. [PMC free article] [PubMed]
8. Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of northern Chile due to arsenic in drinking water. Am J Epidemiol. 1998;147:660–669. [PubMed]
9. Hopenhayn-Rich C, Biggs ML, Fuchs A, et al. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology. 1996;7:117–124. [PubMed]
10. Hopenhayn-Rich C, Biggs ML, Smith AH. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol. 1998;27:561–569. [PubMed]
11. van Geen A, Ahsan H, Horneman AH, et al. Promotion of well-switching to mitigate the current arsenic crisis in Bangladesh. Bull World Health Organ. 2002;80:732–737. [PMC free article] [PubMed]
12. Statistical Yearbook of Bangladesh. Dacca, Bangladesh: Bangladesh Bureau of Statistics; 1999.
13. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. Lyon, France: International Agency for Research on Cancer; 2001. IARC cancer base 5.
14. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18–29. [PubMed]
15. Bangladesh Cancer Epidemiology Research Programme, 1976–1981. In: Parkin DM, ed. Cancer Occurrence in Developing Countries. Lyon, France: International Agency for Research on Cancer; 1986:195–198.
16. Sankaranarayanan R, Black RJ, Parkin DM. Cancer Survival in Developing Countries. Lyon, France: International Agency for Research on Cancer; 1998. IARC scientific publication 145. [PubMed]
17. Morales KH, Ryan L, Kuo TL, Wu MM, Chen CJ. Risk of internal cancers from arsenic in drinking water. Environ Health Perspect. 2000;108:655–661. [PMC free article] [PubMed]
18. Smith AH, Hopenhayn-Rich C, Bates MN, et al. Cancer risks from arsenic in drinking water. Environ Health Perspect. 1992;97:259–267. [PMC free article] [PubMed]
19. United Nations Children’s Fund. Arsenic mitigation in Bangladesh. Available at: http://www.unicef.org/arsenic/. Accessed January 10, 2003.
20. Chappell WR, Beck BD, Brown KG, et al. Inorganic arsenic: a need and an opportunity to improve risk assessment. Environ Health Perspect. 1997;105:1060–1067. [PMC free article] [PubMed]
21. National Research Council, Subcommittee on Arsenic in Drinking Water. Statistical Issues: Arsenic in Drinking Water. Washington, DC: National Academy Press; 1999:264–299.
22. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am J Epidemiol. 1992;135:462–476. [PubMed]
23. Ke-You G, Da Wei F. The magnitude and trends of under- and over-nutrition in Asian countries. Biomed Environ Sci. 2001;14:53–60. [PubMed]
24. Efroymson D, Ahmed S, Townsend J, et al. Hungry for tobacco: an analysis of the economic impact of tobacco consumption on the poor in Bangladesh. Tob Control. 2001;10:212–217. [PMC free article] [PubMed]
25. Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985;45:5895–5899. [PubMed]
26. Rahman M, Amanullah, Sattar H, Rahman M, Rashid HA, Mollah AS. Sero-epidemiological study of hepatitis B virus infection in a village. Bangladesh Med Res Counc Bull. 1997;23:38–41. [PubMed]
27. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet. 1981;2:1129–1133. [PubMed]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
  • Taxonomy
    Taxonomy records associated with the current articles through taxonomic information on related molecular database records (Nucleotide, Protein, Gene, SNP, Structure).
  • Taxonomy Tree
    Taxonomy Tree

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...